SNDL (SNDL) Stock Price, News & Analysis

Company Overview

SNDL Inc., formerly known as Sundial Growers, is a vertically integrated cannabis company headquartered in Calgary, Alberta. The company cultivates, processes and markets a diverse portfolio of adult-use and medical cannabis products. Through its production facilities in Canada, SNDL offers dried flower, pre-rolled joints, oils, vapes and soft-gel capsules under multiple consumer brands, catering to a wide range of preferences and consumption styles.

Under its House of Brands strategy, SNDL markets flagship labels such as Sundial, Top Leaf and Iron Butterfly, alongside specialized lines like Quantum 9 for high-potency offerings. The company also develops value-oriented branded products through partnerships and in-house innovation, with an emphasis on consistent quality control, scalable production methods and ongoing research into novel cannabinoids and formulations.

Distribution is supported by SNDL’s retail network, SpiritLeaf, which operates a growing number of locations across key Canadian provinces. This direct-to-consumer channel complements the company’s wholesale relationships with provincially regulated distributors and private retail partners. Through these combined avenues, SNDL maintains broad market coverage from coast to coast in Canada.

Founded in 2006, the organization transitioned to public ownership in 2018 via a reverse takeover and rebranded as SNDL Inc. Leadership under President and CEO Zach George has expanded the company’s scope beyond cannabis. In March 2023, SNDL acquired Genesus, a global swine genetics enterprise with operations spanning over 40 countries, marking a strategic diversification into agricultural genetics. The company’s executive team continues to pursue growth through product innovation, operational efficiencies and selective acquisitions.

Key Stats

• Today's Range: $1.36 to $1.42
• 50-Day Range: $1.21 to $1.42
• 52-Week Range: $1.15 to $2.40
• Volume: 1.73 million shs
• Average Volume: 1.94 million shs
• Market Capitalization: $365.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.63
• Consensus Rating: Buy

SNDL Stock Analysis - MarketRank™

SNDL scored higher than 61% of companies evaluated by MarketBeat, and ranked 407th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

SNDL has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

SNDL has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SNDL are expected to grow in the coming year, from ($0.09) to ($0.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SNDL is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SNDL is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SNDL has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.21% of the float of SNDL has been sold short.

Short Interest Ratio / Days to Cover

SNDL has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SNDL has recently increased by 10.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SNDL does not currently pay a dividend.

Dividend Growth

SNDL does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.21% of the float of SNDL has been sold short.

Short Interest Ratio / Days to Cover

SNDL has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SNDL has recently increased by 10.83%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.48

News Sentiment

SNDL has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for SNDL this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for SNDL on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added SNDL to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SNDL insiders have not sold or bought any company stock.

SNDL Stock Analysis - Frequently Asked Questions

How have SNDL shares performed this year?

SNDL's stock was trading at $1.79 on January 1st, 2025. Since then, SNDL stock has decreased by 22.3% and is now trading at $1.39.

How were SNDL's earnings last quarter?

SNDL Inc. (NASDAQ:SNDL) issued its quarterly earnings results on Thursday, May, 1st. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. The business had revenue of $142.38 million for the quarter, compared to the consensus estimate of $214.60 million. SNDL had a negative trailing twelve-month return on equity of 9.02% and a negative net margin of 11.48%.
Read the conference call transcript.

When did SNDL's stock split?

Shares of SNDL reverse split on the morning of Tuesday, July 26th 2022.The 1-10 reverse split was announced on Tuesday, July 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did SNDL IPO?

SNDL (SNDL) raised $130 million in an initial public offering on Thursday, August 1st 2019. The company issued 10,000,000 shares at $12.00-$14.00 per share. Cowen, BMO Capital Markets and Barclays acted as the underwriters for the IPO.

How do I buy shares of SNDL?

Shares of SNDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SNDL own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SNDL investors own include Zomedica (ZOM), AMC Entertainment (AMC), NIO (NIO), Meta Platforms (META), Tesla (TSLA), Jumia Technologies (JMIA) and

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNDL
• CIK: 1766600
• Web: www.sundialcannabis.com
• Phone: (844) 249-6746
• Fax: N/A
• Employees: 2,516
• Year Founded: N/A

Price Target and Rating

• Average Price Target for SNDL: $3.63
• High Price Target: $4.00
• Low Price Target: $3.25
• Potential Upside/Downside: +160.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.18 million
• Net Margins: -11.48%
• Pretax Margin: -12.23%
• Return on Equity: -9.02%
• Return on Assets: -7.60%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 4.62
• Quick Ratio: 3.12

Sales & Book Value

• Annual Sales: $671.81 million
• Price / Sales: 0.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.15 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 262,780,000
• Free Float: N/A
• Market Cap: $365.26 million
• Optionable: Optionable
• Beta: 3.40